First-in-Class Treatment for Hyperoxaluria
ALLN-177 is a first-in-class, non-absorbed oral enzyme that specifically degrades oxalate, a known component of most kidney stones (nephrolithiasis). In phase I and phase 2 clinical trials, treatment with ALLN-177 was well tolerated and resulted in a statistically significant reduction in urinary oxalate excretion.
ALLN-177 is being developed for the chronic management of hyperoxaluria in patients with a history of kidney stones. The enzyme targets oxalate in the gastrointestinal tract, degrading oxalate before it can be absorbed. This degradation of oxalate has the potential to decrease the oxalate available systemically and may lower oxalate crystal deposition in the kidneys. Calcium oxalate crystals can also contribute to other forms of renal pathology including oxalate nephropathy and nephrocalcinosis, which are characterized by crystal deposition in the kidney that can cause acute kidney injury and kidney failure.
In addition to treating adult secondary hyperoxaluria, ALLN-177 has received an orphan designation for pediatric hyperoxaluria. Hyperoxaluria is one of the common metabolic abnormalities in pediatric patients with kidney stones. Analogous to adults, the causes of pediatric hyperoxaluria include the genetic primary form of the disease and the underlying enteric and idiopathic causes associated with the secondary form of hyperoxaluria.
Based on positive Phase 1 and 2a data of ALLN-177 in 2015, Allena has initiated two Phase 2 studies of ALLN-177 in adult secondary hyperoxaluria. For more information about ongoing clinical studies visit www.clinicaltrials.gov. To find out if you are eligible to participate in one of the trials, take our brief survey.